Safety Monitoring Committee review of third dose-level cohort allows progression of Phase 1 RAD-18-001 study to fourth and final cohort dose level cohort

Norwegian radiopharmaceutical company announces successful closing of a private placement that will allow the company to initiate the next phase of clinical development of its lead product candidate Radspherin®

Norwegian radiopharmaceutical company is contemplating a private placement to raise funds for the phase 2A development of it’s lead product candidate Radspherin®

7MBq dose of Radspherin® determined to be safe, and approved by the SMC as the recommended clinical dose for repeated injection and expansion cohorts of RAD-18-002 study

Safety Monitoring Committee review of second dose-level cohort allows advancement of Phase 1 RAD-18-001 study to third cohort dose level cohort

Safety Monitoring Committee review of third dose-level cohort allows progression of Phase 1 RAD-18-002 study to fourth and final cohort dose level cohort

Safety Monitoring Committee review of first dose-level cohort allows progression of RAD-18-001 study to second dose level cohort

Safety review of second dose-level cohort allows study to advance to third cohort of colorectal cancer patients with peritoneal carcinomatosis in Radspherin® clinical trial.

Safety review of first dose-level cohort allows progression to second cohort of colorectal cancer patients with peritoneal carcinomatosis in Radspherin® clinical trial.

Radiopharmaceutical company starts first-in-human trial in a second patient population; ovarian cancer patients suffering from peritoneal carcinomatosis Oncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisotope-based therapies to provide new therapeutic options for cancer patients, today announced that a second phase 1 clinical trial of it’s lead candidate compound Radspherin® has been initiated. The first ovarian cancer patient has been treated with Radspherin® at the Radium Hospital in Oslo under the guidance of clinical investigator Dr. Yun Wang, M.D., Ph.D.